Pds biotech to host key opinion leader roundtable addressing current and future treatments for recurrent/metastatic hpv-positive hnscc and the potential application of pds0101 on september 27, 2023

Company to provide updated versatile-002 data on combination of pds0101 and keytruda® company to provide updated versatile-002 data on combination of pds0101 and keytruda®

PDSB Ratings Summary

PDSB Quant Ranking